Skip to main content
SpringerLink
Log in

Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system

  • Session II: Treatment for Inoperable Patients TACE, Infusion Reservoir and Radiotherapy
  • Hepatic Arterial Infusion, Implantable Port System, Liver Metastases
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Between 1985 and 1990, 50 patients with unresetable liver metastases from colorectal cancer and 34 subjects with metastases from gastric cancer were treated by repeated hepatic arterial infusion chemotherapy employing an implantable prot system. A catheter was inserted into the hepatic artery via the left subclavian artery and was connected to the implantable injection port in each patient. 5-Fluorouracil (5-FU) at 330 mg/m2 per week (167 mg/m2 daily given continuously over the initial 3 months for colorectal cancer), Adriamycin (ADR) at 20 mg/m2 every 4 weeks and mitomycin C (MMC) at 2.7 mg/m2 every 2 weeks were given to all 34 patients with gastric cancer and to 31 of the colorectal cancer patients. The remaining 19 patients with colorectal cancer received 5-FU at 1.000 mg/m2 every week. As a rule the treatment was performed on an outpatient basis. The side effects and complications observed included myelosuppression (23%), hepatic arterial occlusion (21%), and gastroduodenal mucositis (12 %), although no major toxicity was encountered. The response rate (CR+PR) among the evaluated patients as detemined using CT scans was 67% for colorectal cancer and 73% for gastric cancer. The overall median survival was 12 months and 15 months, respectively. Good local control of liver metastases from the colorectal and gastric cancers was achieved by repeated hepatic arterial infusion chemotherapy employing an implantable port system without the need for hospitalization and without producing major toxicity. Thus, the implantable port system is very useful for the management of patients with unresectable liver metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arai Y, Kamimura N, Suyama K (1982) A method for subcutaneously retaining a catheter connected to a new silicone reservoir in intra-arterial infusion chemotherapy. Jpn J Cancer Chemother 9: 1838

    Google Scholar 

  2. Arai Y, Kido C, Endo T, Miyake Y, Ariyoshi Y, Fukushima M (1988) Hepatic arterial infusion (HAI) chemotherapy for liver metastasis from colon, gastric and breast cancer (ca). Proc Am Soc Clin Oncol 7:102

    Google Scholar 

  3. Arai Y, Endo T, Miyake Y, Kido C, Ariyoshi Y (1990) A phase I trial of 5 hours hepatic arterial infusion (HAI) of high dose 5FU in weekly schedule for liver metastases from colorectal cancer (LMCRC). Proc Am Soc Clin Oncol 9:113

    Google Scholar 

  4. Arai Y, Endo T, Miyake Y, Sakamoto K, Tagaya T, Kido C (1990) A study of technical problems in hepatic arterial infusion chemotherapy using percutaneous approach. Jpn J Med Imaging 9:114

    Google Scholar 

  5. Arai Y, Sone Y, Tohyama N, Kido C, Ariyoshi Y (1991) A phase II study of 5 hours hepatic arterial infusion (HAI) of high dose 5FU in weekly schedule for liver metastases from colorectal cancer (LMCRC). Proc Am Soc Clin Oncol 10:142

    Google Scholar 

  6. Buchwald H, Grage TB, Vassilopoulus PP, Rohde TD, Varco RL, Blackshear PJ (1980) Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 45:866

    Google Scholar 

  7. Chang AE, Schneider PO, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapyin the treatment of colorectal liver metastases. Ann Surg 206:685

    Google Scholar 

  8. Gyves J, Ensminger W, Niederhuber J, Liepman M, Cozzi E, Doan K, Dakhil S, Wheeler R (1982) Totally implanted system for intravenous chemotherapy in patients with cancer. Am J Med 73:841

    Google Scholar 

  9. Hohn DC, Stagg RJ, Friedman MA, Hannigan JR Jr. Rayner A, Ignoffo RJ, Acord P, Lewis BJ (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7:1646

    Google Scholar 

  10. Katz A, Gansl R, Simon S, Gama-Rodrigues JJ, Waitzberg D, Breseiani C, Pinotti HV (1989) Phase II trial of VP-16 (V), Adriamycin (A) and cisplatinum (C) in patients (PTS) with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 8:98

    Google Scholar 

  11. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107:459

    Google Scholar 

  12. Lerner A, Steele GD, Mayer RJ (1990) Etoposide, doxorubicin, cisplatin (EAP) chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. Proc Am Soc Clin Oncol 9:103

    Google Scholar 

  13. MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS (1979) 5-Fluorouracil, Adriamycin and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44:42

    Google Scholar 

  14. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HS (1986) A phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4:1053

    Google Scholar 

  15. O'Connell MJ, Mailliard J, Martin J, Fitzgibbons R, Nagorney D, Wieand H, Tschetter L, Krook J (1989) A controlled trial of regional intra-arterial FUDR versus systemic 5FU for the treatment of metastatic colorectal cancer confined to the liver. Proc Am Soc Clin Oncol 8:98

    Google Scholar 

  16. Ogawa M, Taguchi T (1985) 18 upper gastrointestinal tumors. In: Cancer chemotherapy vol 17. Excerpta Medica, Amsterdam, p 322

    Google Scholar 

  17. Ogawa M, Taguchi T (1988) 17 upper gastrointestinal tumors. In: Cancer chemotherapy and biological response modifiers, vol 10. Excerpta Medica, Amsterdam, p 241

    Google Scholar 

  18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649

    Google Scholar 

  19. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer H-J, Buente H (1989) Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310

    Google Scholar 

  20. Reed ML, Vaitkevicius VK, Al-Sarraf M, Vaughn CB, Singhakowinta A, Sexon-Porte M, Izbicki R, Baker L, Straatsma GW (1981) The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer 47:402

    Google Scholar 

  21. Taguchi T (1989) Combination chemotherapy with etoposide (E), Adriamycin (A) and cisplatin (P) (EAP) for advanced gastric cancer. Proc Am Soc Clin Oncol 8:108

    Google Scholar 

  22. Wagener DJT, Yap SH, Wobbes T, Burghouts JTM Dam FE van, Hillen HFP, Hoogendoorn GJ, Scheerder H, Vegt SGL van der (1985) Phase II trial of 5-fluorouracil, Adriamycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15: 86

    Google Scholar 

  23. Woolley P, Smith F, Estevez R, Gisselbrecht C, Alvarez C, Boiron M, Machado C, Lagarde C, Schein P (1981) A phase II trial of 5-FU, Adriamycin and cisplatin (FAP) in advanced gastric cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 22:455

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464, Nagoya, Japan

    Yasuaki Arai, Yasuhiro Sone, Norihiro Tohyama, Yoshitaka Inaba, Satoru Kohno & Choichiro Kido

  2. Department of Radiology, Nagoya University School of Medicine, Nagoya, Japan

    Tokiko Endo

  3. Department of Hematology and Chemotherapy, Aichi Cancer Center, Nagoya, Japan

    Yutaka Ariyoshi

Authors
  1. Yasuaki Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tokiko Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhiro Sone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norihiro Tohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshitaka Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satoru Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yutaka Ariyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Choichiro Kido
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arai, Y., Endo, T., Sone, Y. et al. Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system. Cancer Chemother. Pharmacol. 31 (Suppl 1), S99–S102 (1992). https://doi.org/10.1007/BF00687116

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00687116

Keywords

Search

Navigation